Pretreatment assessment of prognostic indicators in endometrial cancer
- 1 June 2000
- journal article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 182 (6) , 1535-1544
- https://doi.org/10.1067/mob.2000.107328
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- HER-2/neu, P53, and DNA analyses as prognosticators for survival in endometrial carcinomaPublished by Wolters Kluwer Health ,2002
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- Lack of bcl-2 Persistence: An Independent Prognostic Indicator of Poor Prognosis in Endometrial CarcinomaGynecologic Oncology, 1998
- Staging and Therapeutic Value of Lymphadenectomy in Endometrial CancerGynecologic Oncology, 1998
- Bcl-2 expression and prognosis of patients with endometrial carcinomaInternational Journal of Cancer, 1998
- Prognostic Value of p53 and Proliferating Cell Nuclear Antigen Expression in Endometrial CarcinomaGynecologic Oncology, 1996
- Proliferation Index Determined by MIB-1 and Recurrence in Endometrial CancerGynecologic Oncology, 1996
- Deoxyribonucleic acid analysis facilitates the pretreatment identification of high-risk endometrial cancer patientsAmerican Journal of Obstetrics and Gynecology, 1993
- HER-2/neu expression: A major prognostic factor in endometrial cancerGynecologic Oncology, 1992
- DNA Ploidy in Endometrial Carcinoma: Major Objective Prognostic FactorMayo Clinic Proceedings, 1990